CA2142861C - Novel uses of il-4 and/or il-10, and antibodies against the same - Google Patents

Novel uses of il-4 and/or il-10, and antibodies against the same Download PDF

Info

Publication number
CA2142861C
CA2142861C CA002142861A CA2142861A CA2142861C CA 2142861 C CA2142861 C CA 2142861C CA 002142861 A CA002142861 A CA 002142861A CA 2142861 A CA2142861 A CA 2142861A CA 2142861 C CA2142861 C CA 2142861C
Authority
CA
Canada
Prior art keywords
cells
cell
human
mice
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002142861A
Other languages
English (en)
French (fr)
Other versions
CA2142861A1 (en
Inventor
Robert Coffman
Jan E. De Vries
Rene De Waal Malefyt
Fiona Powrie
Donna Rennick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/932,900 external-priority patent/US5368854A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of CA2142861A1 publication Critical patent/CA2142861A1/en
Application granted granted Critical
Publication of CA2142861C publication Critical patent/CA2142861C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
CA002142861A 1992-08-20 1993-08-18 Novel uses of il-4 and/or il-10, and antibodies against the same Expired - Fee Related CA2142861C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US07/932,900 US5368854A (en) 1992-08-20 1992-08-20 Use of IL-10 to treat inflammatory bowel disease
US07/932,900 1992-08-20
US93341992A 1992-08-21 1992-08-21
US93395092A 1992-08-21 1992-08-21
US93346292A 1992-08-21 1992-08-21
US07/933,950 1992-08-21
US07/933,419 1992-08-21
US07/933,462 1992-08-21
PCT/US1993/007646 WO1994004180A2 (en) 1992-08-20 1993-08-18 Novel uses of il-4 and/or il-10, and antibodies against the same

Publications (2)

Publication Number Publication Date
CA2142861A1 CA2142861A1 (en) 1994-03-03
CA2142861C true CA2142861C (en) 2000-08-15

Family

ID=27506019

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002142861A Expired - Fee Related CA2142861C (en) 1992-08-20 1993-08-18 Novel uses of il-4 and/or il-10, and antibodies against the same

Country Status (23)

Country Link
EP (2) EP0801951A3 (cs)
JP (1) JP3494647B2 (cs)
KR (1) KR0170037B1 (cs)
CN (1) CN1090204A (cs)
AT (1) ATE162947T1 (cs)
AU (1) AU680628B2 (cs)
CA (1) CA2142861C (cs)
CZ (1) CZ283488B6 (cs)
DE (1) DE69316921T2 (cs)
DK (1) DK0671933T3 (cs)
ES (1) ES2111769T3 (cs)
FI (1) FI950697L (cs)
GR (1) GR3026635T3 (cs)
HK (1) HK1004326A1 (cs)
HU (1) HU220103B (cs)
IL (1) IL106725A (cs)
MX (1) MX9305054A (cs)
MY (1) MY111402A (cs)
PL (1) PL307566A1 (cs)
RU (1) RU2120802C1 (cs)
SK (1) SK21195A3 (cs)
TW (1) TW243415B (cs)
WO (1) WO1994004180A2 (cs)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510719A (ja) * 1993-02-01 1996-11-12 ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用
CA2194444C (en) * 1994-07-05 2003-01-14 Christian Gronhoj Larsen Immunomodulators
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
EP0793504B1 (en) * 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
EP0756871A1 (en) * 1995-08-01 1997-02-05 Institut Pasteur Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
WO1997038695A1 (en) * 1996-04-17 1997-10-23 Prendergast Patrick T Dhea combination therapy
WO1998027997A1 (en) * 1996-12-20 1998-07-02 Magainin Pharmaceuticals Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
AU770726B2 (en) * 1998-10-20 2004-02-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
RU2140283C1 (ru) * 1998-12-15 1999-10-27 Товарищество с ограниченной ответственностью "Биотех" Фармацевтический препарат на основе интерлейкина-2 (варианты)
IL144826A0 (en) 1999-02-10 2002-06-30 Welfide Corp Amide compounds and pharmaceutical compositions containing the same
AU4903801A (en) * 1999-12-03 2001-07-09 Baxter International Inc. Pyrogenicity test for use with automated immunoassay systems
AU8729101A (en) 2000-03-31 2001-10-15 Idec Pharma Corp Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma
US6797263B2 (en) 2000-05-12 2004-09-28 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
RU2196605C2 (ru) * 2000-12-07 2003-01-20 Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера Способ получения растворимых конъюгатов биологически активных веществ
RU2202363C2 (ru) * 2001-04-09 2003-04-20 Ершов Феликс Иванович Способ определения чувствительности живого организма и/или его клеток к воздействию вещества, поля или комбинации веществ и/или полей
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2005047324A2 (en) * 2003-11-10 2005-05-26 Schering Corp Interleukin-10 antibodies
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
PE20060560A1 (es) 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
CA2609617C (en) 2005-05-31 2014-07-08 The Iams Company Feline probiotic lactobacilli
ES2399987T3 (es) * 2005-10-03 2013-04-04 Actogenix N.V. Uso de una cepa de levadura recombinante que produce un compuesto antiinflamatorio en la fabricación de un medicamento para tratar colitis
NZ597098A (en) * 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
CA2673465A1 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
HK1215681A1 (zh) * 2013-04-18 2016-09-09 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
LT3369435T (lt) 2013-07-18 2020-01-10 Xalud Therapeutics, Inc. Kompozicija uždegiminės sąnarių ligos gydymui
JP6509867B2 (ja) 2013-08-30 2019-05-08 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためにインターロイキン−１０を使用する方法
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
CN114349858B (zh) * 2022-01-26 2022-07-01 优睿赛思(武汉)生物科技有限公司 抗人白介素-10高亲和力兔单克隆抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
SK279556B6 (sk) * 1991-01-16 1998-12-02 Schering Corporation Liečivo na liečenie nádorov pacienta
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair

Also Published As

Publication number Publication date
WO1994004180A3 (en) 1994-06-09
IL106725A (en) 2000-12-06
JP3494647B2 (ja) 2004-02-09
CN1090204A (zh) 1994-08-03
AU680628B2 (en) 1997-08-07
CZ283488B6 (cs) 1998-04-15
HU220103B (hu) 2001-10-28
PL307566A1 (en) 1995-05-29
MX9305054A (es) 1994-02-28
SK21195A3 (en) 1996-10-02
EP0671933A1 (en) 1995-09-20
FI950697A7 (fi) 1995-04-07
WO1994004180A2 (en) 1994-03-03
GR3026635T3 (en) 1998-07-31
DE69316921T2 (de) 1998-06-04
KR0170037B1 (ko) 1999-02-01
DE69316921D1 (de) 1998-03-12
RU95108330A (ru) 1996-11-27
TW243415B (cs) 1995-03-21
HU9500467D0 (en) 1995-04-28
FI950697L (fi) 1995-04-07
CA2142861A1 (en) 1994-03-03
AU5010893A (en) 1994-03-15
EP0801951A3 (en) 1998-05-20
ES2111769T3 (es) 1998-03-16
HUT70976A (en) 1995-11-28
MY111402A (en) 2000-04-29
JPH08500362A (ja) 1996-01-16
FI950697A0 (fi) 1995-02-16
DK0671933T3 (da) 1998-09-23
IL106725A0 (en) 1993-12-08
RU2120802C1 (ru) 1998-10-27
EP0801951A2 (en) 1997-10-22
CZ44195A3 (en) 1995-10-18
ATE162947T1 (de) 1998-02-15
HK1004326A1 (en) 1998-11-20
KR950702841A (ko) 1995-08-23
EP0671933B1 (en) 1998-02-04

Similar Documents

Publication Publication Date Title
CA2142861C (en) Novel uses of il-4 and/or il-10, and antibodies against the same
Grabstein et al. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody.
Davidson et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice.
Blazar et al. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice
Van Snick Interleukin-6: an overview
Shankar et al. T cell and non-T cell compartments can independently determine resistance to Leishmania major.
HK1004326B (en) Novel uses of il-10
JPH07508179A (ja) ヒトインターロイキン−１３
US5837293A (en) Use of interleukin-10 analogs for antagonists to treat endotoxin- or superantigen-induced toxicity
EP1137766A1 (en) Animal model for psoriasis for the prevention and treatment of psoriasis in humans
EP0600970B1 (en) Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity
Coéffier et al. Role of interleukin‐5 in enhanced migration of eosinophils from airways of immunized guinea‐pigs
Rocha et al. Interleukin 2 receptor expression and interleukin 2 production in exponentially growing T cells: major differences between in vivo and in vitro proliferating T lymphocytes
NZ255757A (en) Compositions and methods for the use of il-4 and/or il-10 and antibodies against these cytokines
US6319493B1 (en) Treatment of neoplastic disease with interleukin-10
Dean et al. Pre-clinical toxicity of IL-4: A model for studying protein therapeutics
Schneider et al. Severe Graft‐Versus‐Host Disease in SCID Mice is Associated with a Decrease of Selective Donor Cell TCR Vβ Specificities and Increased Expression of IFN‐γ and IL‐4
Ingram Identification and characterization of a unique subpopulation of double negative splenic T cells which express the [alpha beta] T cell receptor
Grabstein Inhibition of Murine B and T Lymphopoiesis In Vivo by an Anti-Interleukln 7 Monoclonal Antibody By Kenneth H. Grabstein, Thomas J. Waldschmidt,* Fred D. Finkelman,~ Bruce W. Hess, Alan R. Alpert, Norman E. Boiani, Anthony E. Namen, and Philip J. Morrissey
Yang et al. Human Interleukin-15 Improves

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed